dostarlimab

Dostarlimab is a humanized IgG4 monoclonal antibody that functions as an immune checkpoint inhibitor targeting the programmed death receptor-1 (PD-1) on T-cells. By binding to PD-1, dostarlimab blocks its interaction with PD-L1 and PD-L2 ligands, which are often overexpressed by cancer cells to evade immune detection. This blockade restores T-cell activity against tumor cells, enhancing the body's endogenous anti-tumor immune response. Dostarlimab is primarily indicated for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progressed following platinum-containing chemotherapy, either as monotherapy or in combination with carboplatin and paclitaxel. It is also approved for dMMR recurrent or advanced solid tumors in adults who have progressed after prior treatment and lack satisfactory alternative options. The drug was developed using CDR grafting technology from mouse antibodies and exhibits a serum half-life of approximately 25 days. Dostarlimab has demonstrated efficacy in clinical trials such as the GARNET trial, showing significant tumor reduction rates in endometrial cancer patients.

Brand names

Jemperli

Other names

dostarlimab-gxly